CORSICA BUKU YANG BERKAIT DENGAN «MYELOFIBROTIC»
Ketahui penggunaan
myelofibrotic dalam pilihan bibliografi berikut. Buku yang berkait dengan
myelofibrotic dan ekstrak ringkas dari yang sama untuk menyediakan konteks penggunaannya dalam kesusasteraan Corsica.
1
Myeloproliferative Disorders: Biology and Management
Inparticular,when comparing the relative risks and odds ratios (112) for
myelofibrotic progression between the UK-PT1 trial results and our own data,
significant differences could be observed. The mean odds ratio for progression in
the UK-PT1 ...
Richard T. Silver, Ayalew Tefferi,
2007
2
Osteoimmunology: Interactions of the Immune and skeletal ...
Perhaps most surprising is the dramatic phenotype manifested in these mice, as
a myelofibrotic syndrome with osteosclerosis develops by nine months of age in
mice repeatedly injected with TPO, or infected with a viral vector harboring the ...
3
Vitamin D: Molecular, Cellular and Clinical Endocrinology. ...
la,25-DIHYDROXYVITAMIN 03 SYNTHESIS BY NORMAL AND
MYELOFIBROTIC HUMAN SPLEEN CELLS. M.E.Hayes, M.Davies, J.A.Liu-Yin*
and E.B.Mawer. Departments of Medicine and Haematology*, Manchester
University, Manchester ...
A. W. Norman, K. Schaefer, H. G. Grigoleit,
1988
4
Postgraduate Haematology
Finally, the WHO recognizes two additional histological subtypes of MDS, namely
hypoplastic MDS and myelofibrotic MDS, each of which account for
approximately 10% of cases. Hypoplastic MDS has no independent prognostic
significance ...
A. Victor Hoffbrand, Daniel Catovsky, Edward G. D. Tuddenham,
2011
5
Diagnostic Techniques in Hematological Malignancies
Anagrelide therapy has been associated with increasing bone marrow fibrosis
and a risk of myelofibrotic transformation compared to hydroxycarbamide [14]. As
the increase in fibrosis is reversible in some caseson cessation of anagrelide [13]
, ...
6
Myeloproliferative Neoplasms: Critical Concepts and Management
The MPNs have a variable period of risk of vascular events and a long-term risk
of transformation to an overt myelofibrotic phase, acute leukemia, or death (Fig.
12.1). Current available therapies have rarely been able to impact this natural ...
Tiziano Barbui, Ayalew Tefferi,
2012
7
Disorders of Thrombosis and Hemostasis in Pregnancy: A Guide ...
... potential of hydroxycarbamide [10]. Whether treatment strategies can influence
the risk of myelofibrotic transformation is currently the subject of debate.
Pregnancy does not affect the risk of either leukemic or myelofibrotic
transformation.
Hannah Cohen, Patrick O'Brien,
2012
8
Myeloproliferative Neoplasms: Biology and Therapy
The only clinical parameter that has been associated with an abnormal karyotype
appears to be age, in contrast to thrombosis, haemorrhage, leukaemic or
myelofibrotic transformation, JAK2 V617F allele burden or survival [6]. However,
rare ...
Srdan Verstovsek, Ayalew Tefferi,
2010
9
Molecular Basis of Chronic Myeloproliferative Disorders: ...
17.2 Promotion of Bone Marrow Fibrosis In MMM, immunolocalization studies
have demonstrated a marked neovasculariza- tion in the myelofibrotic bone
marrow stroma together with an increased deposition of collagen types I, III, IV, V
and VI, ...
P.E. Petrides, H.L. Pahl,
2004
10
Current Approaches to Bone Marrow Histopathology
MF OMS Figure 7 Histologic subdivisions in MF'OMS, their frequency and median
survivals: a) myelofibrotic without new bone formation (MF). 59%. 55 months; b)
myelofibrotic with new bone formation (OMS). 41% 63 months. Figure 8 ...
Stuart Roath, M. Corn,
1989
BARANGAN BERITA YANG TERMASUK TERMA «MYELOFIBROTIC»
Ketahui apa yang diterbitkan oleh akhbar nasional dan antarabangsa dan cara istilah
myelofibrotic digunakan dalam konteks perkara berita berikut.
Incyte Pharmaceutical: Top Idea For 2H14 With 2 Free Call Options …
... status measures represents a significant value driver in pancreatic cancer and (Myelofibrotic Disorders) by enabling patients to stay healthier, ... «Seeking Alpha, Sep 14»
Anagrelide Also Found Effective for Essential Thrombocythemia
This study does appear to validate the value of differentiation between WHO-ET and early prefibrotic myelofibrosis, which suggests that the risk for myelofibrotic ... «Clinical Oncology News, Jun 13»